My Performance Edge – Week 19. Exosomes, the Messages that tell the Body what to do

by Kevin Kearns, contributing writer

We hear the word exosomes everywhere in regenerative medicine right now.

But what exactly are they? And maybe the more important question is:

Are all exosomes the same?

Absolutely not.

THINK OF THEM AS CELLULAR MESSENGERS

Your cells are constantly communicating. One of the ways they do that is through tiny membrane-bound particles called extracellular vesicles (EVs). Exosomes are a subtype of these nanoscale vesicles produced through a specific cellular pathway.

They can carry biological cargo including:

• Proteins
  • Lipids
  • Messenger RNA
  • MicroRNA
  • Other signaling molecules

Think of the cell as the command center and the exosome as one of its biological delivery vehicles.

The message it carries can influence what happens when it reaches another cell. That cell-to-cell communication is one reason exosomes have attracted so much attention in regenerative medicine.

WHY IS THE REGENERATIVE-MEDICINE WORLD SO INTERESTED?

Researchers are investigating extracellular vesicles derived from mesenchymal stromal cells because they may reproduce some of the paracrine signaling associated with the cells themselves—without administering the intact cells.

Preclinical research has explored their potential influence on:

• Inflammatory signaling
  • Immune modulation
  • Angiogenesis
  • Tissue-repair pathways
  • Wound healing
  • Cartilage and musculoskeletal repair
  • Cellular survival and recovery

That doesn’t mean exosomes have been proven to treat all of these conditions in humans. That’s an important distinction.

The science is promising, but clinical translation is still developing. Human studies remain relatively small and heterogeneous, and researchers are still working to establish standardized dosing, manufacturing, characterization and potency testing.

HERE’S WHERE IT GETS REALLY INTERESTING

Not all exosomes are created equal.

Seeing the word EXOSOMES on a vial tells you very little about the actual biological product.

The characteristics of an extracellular-vesicle preparation can be influenced by:

• The cells it came from
  • How those cells were cultured
  • The health and characteristics of the source cells
  • Collection methods
  • Isolation and purification
  • Particle concentration
  • Cargo composition
  • Manufacturing consistency
  • Storage and handling
  • Quality-control testing

In other words:

SOURCE MATTERS.
PROCESS MATTERS.
PURITY MATTERS.
CHARACTERIZATION MATTERS.

This is where education needs to replace hype.

MORE ISN’T AUTOMATICALLY BETTER

You will hear companies talk about enormous numbers of exosome particles. Billions. Trillions. Those numbers sound impressive. But particle count alone doesn’t establish biological potency or clinical effectiveness.

Researchers are actively working toward better potency assays and standardized ways of measuring extracellular-vesicle preparations because quantity and biological activity are not necessarily the same thing.

For me, that’s one of the most important lessons in this entire space.

Don’t just ask:

“How many exosomes are in it?”

Ask:

Where did they come from? How were they produced? How were they purified and characterized? What quality-control documentation exists? And what evidence supports the intended application?

CELL THERAPY VS. CELLULAR SIGNALING

This also helps explain an important difference between the regenerative technologies we’ve been discussing.

Stem-cell-based therapies involve living cells.

Exosome/EV approaches are generally considered cell-free strategies involving biological particles released by cells.

They aren’t interchangeable. They may ultimately play very different roles in regenerative medicine. And next week we’re going to take that discussion another step further when we look at something most people have never heard of:

MUSE CELLS.

We’ll look at what they are, how researchers distinguish them from conventional mesenchymal stromal/stem cells, and why they’re generating interest in regenerative medicine.

ONE FINAL POINT: SCIENCE BEFORE SALES

Exosome research is moving quickly, but enthusiasm should never outrun evidence.

In the United States, there are currently no FDA-approved exosome products for treating diseases or conditions. Much of the therapeutic work involving exosomes and extracellular vesicles remains investigational.

That’s exactly why education, manufacturing standards, documentation and transparency matter. The future of regenerative medicine isn’t about finding the product with the biggest marketing claim.

It’s about understanding the biology.

Know the source.
Know the science.
Know the process.
Know what you’re putting into your body.

That’s the difference between chasing hype and making an educated decision.

This is My Performance Edge.

BWKAuthenticEdge.com

#MyPerformanceEdge #Exosomes #RegenerativeMedicine #Longevity

___

#Longevity #StrengthTraining #HealthyAging #Peptides

Kevin Kearns has worked in the health, fitness and human-performance field for more than three decades. This column is for educational purposes only and does not constitute medical advice. BPC-157 is investigational and is not FDA-approved for treating surgical wounds, musculoskeletal injuries or other medical conditions.